CLINICAL AND ULTRASOUND CHARACTERISTICS AND COMPREHENSIVE TREATMENT OF WOMEN OF REPRODUCTIVE AGE WITH ADHESION PROCESS OF THE PELVIC ORGANS
Kharkiv Medical Academy of Postgraduate Education, Ukraine
Adhesions of pelvic organs in women result in functional disturbances in the organs themselves and eventually in their morphostructural changes. The aim of the work was to study the clinical efficacy of «Longidaze®» as a monotherapy and as a combined treatment with physical therapy in women of reproductive age with adhesions of pelvic organs. The study involved 85 women of reproductive age with adhesions of pelvic organs, which were divided into group 1 and 2, the main group (n = 30) and control group. Depending on the method of treatment, the patients were divided into groups 1A, I B, each of 15 patients, and group 2A and 2B, similarly. Treatment of patients from group 1A and 2A was carried out by IM injections of Longidaze®, 3000 IU 1 time in 3−5 days, No.10, as monotherapy. Patients from groups 1B and 2B were treated IM injections of Longidaze®, 3000 IU 1 time every 3−5 days No.5, in combination with phonophoresis with the drug to the area of the uterus and appendages projection at a dose of 3000 IU a day, by a course of at least 10−15 procedures. Use as a combination treatment with Longidaze® in patients of groups 1B and 2 B at least by 10−15 procedures contributed to a more accurate visualization of organs at ultrasonography, reduced pain in 26 (86.6 %) patients, phenomena of dyspareunia in 19 (63.3 %) patients after 5−7 treatment procedures, and 2 times shortened the duration of treatment of patients with adhesions of the pelvic organs. Combined use of Longidaze® with phonophoresis with the drug according to the developed protocol, potentiates the effect of the drug, increasing its bioavailability and can significantly reduce the time of treatment of women of reproductive age with adhesive process of the pelvic organs.
Key words: adhesion process of the pelvic organs, transvaginal ultrasonography, combined treatment, "Longidaze®", women of reproductive age.